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Whole Women’s Victory — or Not?
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zales, the Court upheld the federal
statute in part because “a fetus is
a living organism within the
womb, whether or not it is viable
outside the womb” and “choosing not to prohibit [a brutal and
inhumane procedure] will further
coarsen society to the humanity
of not only newborns, but all
vulnerable and innocent human
life, making it increasingly difficult to protect such life.” One
can easily imagine
An audio interview
with Dr. Charo is
similar language in
available at NEJM.org
a decision that upholds prohibitions on second-trimester D&E procedures or 20-week
bans by deferring to disputed legislative findings about fetal pain.
This scenario is not idle speculation. The Zika virus can have

devastating effects on fetal development that cannot be detected
until well into the second trimester. If courts fail to examine the
real motivations behind the spate
of new laws premised on fetal
pain and therefore uphold 20-week
bans, anesthesia requirements, or
procedure limitations out of judicial deference to legislative findings, the Whole Woman’s Health decision would no longer be a whole
women’s victory.
Disclosure forms provided by the author
are available at NEJM.org.
From the School of Law and the Department of Medical History and Bioethics,
School of Medicine and Public Health, University of Wisconsin, Madison.
This article was published on August 10,
2016, at NEJM.org.
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M

r. M. was hospitalized with
endocarditis caused by his
use of injected opioids. After receiving two valve replacements,
he remained in the hospital for
several weeks — even after his
condition had stabilized — to
complete a course of antibiotics,
because there was no other option for transitional care. During
his admission, addiction counselors recommended that he receive
abstinence-based treatment after
discharge. Mr. M. was not interested in such treatment, however,
and repeatedly requested opioids
for pain and withdrawal symptoms. These requests, which the
care team interpreted as “drugseeking behavior” that should not
be reinforced, caused conflicts between Mr. M. and his clinicians.
As Mr. M. began to feel better,

he spent less time in his room
and more time walking the halls
and venturing outside the hospital building, arousing concern that
he was obtaining and using illicit
opioids. Nursing staff requested
that hospital security conduct
room searches, and the physician
team asked Mr. M. to sign a behavioral contract promising to refrain from illicit drug use.
After discharge, Mr. M. did
not keep his follow-up appointments, continued to inject opioids,
and was admitted months later
with prosthetic-valve endocarditis.
Though a repeat valve-replacement
procedure was performed, he died
from complications of endocarditis after another prolonged hospitalization.
This unfortunate outcome was
not entirely unexpected. The risk
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of death or reoperation between
90 and 180 days after an index
surgery for endocarditis is 10 times
as high among persons who inject
drugs as among those who do
not.1 These outcomes probably reflect inadequately treated addiction, ongoing injection-drug use,
and potential overdose. It is premature to argue that treating
such patients for infections is
medically futile and wasteful of
resources when their underlying
opioid-use disorder (OUD) has not
yet been treated in an evidencebased manner. Typically, the focus
of the hospitalization is on managing the infection,2 and common
interventions related to OUD, such
as restricting pain medications
and the patient’s mobility, not only
erode the doctor–patient relationship but are also ineffective. This

September 1, 2016

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF KENTUCKY on January 5, 2018. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.

811

Putting Parity into Practice

PERS PE C T IV E

dynamic, along with undertreated
pain and opioid withdrawal, probably contributes to the high rates
of discharge against medical advice (11 to 12%) among hospitalized patients with OUD.3
Hospitalizations for severe infections associated with OUD,
such as endocarditis and osteomyelitis, have doubled in the
United States over the past decade
and are frequently prolonged and
resource-intensive.3 Once their condition has stabilized, most patients
with such infections complete intravenous antibiotic therapy either
at home with home health support or in a postacute care facility.
But patients with medically and
psychosocially complex conditions, such as OUD, are often
denied admission to skilled nursing facilities,3 and residential
addiction-treatment programs are
generally not equipped to manage coexisting medical illnesses.
These constraints, coupled with
concerns that such patients will
continue to use injected opioids
and will fail to adhere to an antibiotic regimen after discharge,
mean that they often remain in
the hospital for weeks while receiving intravenous antibiotics.3
This costly clinical choice is intended to be the safest option;
however, without simultaneous
treatment of OUD — the underlying cause of the infection — a
host of other problems ensue.
We believe there is an urgent
need to integrate evidence-based
medication-assisted treatment
(MAT) for OUD — naltrexone,
buprenorphine, or methadone
therapy — into hospital care.
MAT has been shown to reduce
illicit opioid use and related morbidity and mortality.4 In addition,
methadone and buprenorphine
help in managing pain and withdrawal, which could reduce clinician–patient conflict, help engage
812

patients in care, and reduce the
number of discharges that occur
against medical advice. Research
has shown that buprenorphine
treatment for OUD can be initiated successfully in acute care settings such as emergency departments and then continued on an
outpatient basis.5
Since relapse rates without
MAT (in detoxification or abstinence-only programs) exceed 80%,4
it seems logical to initiate MAT
during hospitalization — though
doing so won’t be easy. The many
barriers include the limited availability of outpatient buprenorphine providers and licensed
methadone clinics, as well as difficulties with insurance coverage.
Furthermore, stringent federal privacy regulations specific to the
treatment of substance-use disorder, though intended to protect
patients, effectively segregate such
treatment from general medical
care, thereby impeding the development of integrated care systems.
Implementing evidence-based
care for hospitalized patients with
OUD may substantially improve
outcomes and reduce costs. A
reasonable first step is to ensure
that all patients admitted to the
hospital with an opioid overdose,
or a medical illness with concomitant opioid use, receive a
comprehensive assessment for
substance-use disorder. If there
is a current diagnosis of OUD,
we believe that informed consent
and initiation of MAT for OUD
should be a priority.
Some patients may not want
to accept MAT even if it is recommended, but health care providers can still apply harm-reduction
practices such as standardized
treatment of pain and withdrawal
during hospitalization; education
of patients and families about
how to inject safely, how to obtain clean needles, and how to
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avoid, recognize, and treat opioid
overdose; and provision at discharge of prescriptions for intranasal naloxone. These simple actions can reduce morbidity and
mortality and communicate that
the health care community is invested in treating and minimizing complications of OUD. Demonstrating with our actions that
we know OUD is an illness rather than a moral failing is critical
for patients. That message differs
greatly from the one that was
sent to Mr. M.
Clinical research is also urgently needed. People who inject
drugs have been excluded from
studies of outpatient parenteral
antibiotic therapy — an omission
that leaves providers without an
evidence base to support ambulatory transitional management of
infections. There are no data to
suggest that keeping these patients
in the hospital affects rates of
completion of antibiotic treatment
or of reoperation or that doing
so prevents illicit drug use. There
may in fact be harm associated
with prolonged hospitalization,
such as increased risk of opioid
overdose because of reduced physiological tolerance after weeks of
relative opioid abstinence in the
hospital; there are reports of fatal overdoses after people who
inject drugs leave jails or detox
programs.
Additional research is needed
to better define the underlying
substance-use disorders, motivations for treatment, and available
social support to help guide treatment of patients admitted to the
hospital with infections and OUD.
We must also effectively address
the treatment of pain, an often
complex but essential aspect of
care, if we are to keep patients
engaged. Perhaps patients who
are highly motivated, are accepting of MAT, and have social
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support to assist with ongoing
medical treatment would be candidates for innovative transitional
care programs aimed at supporting remission of OUD, avoiding
reinfection, and reducing costs.
The unfortunate case of Mr. M.
highlights the fact that the current approach to hospitalized patients with OUD and infections
is far from optimal. Hospitals
will have to be part of any comprehensive plan to address the
opioid epidemic. Currently, we are
not routinely assessing the severity or treatment needs of the underlying OUD, initiating evidencebased treatments, and supporting
risk reduction. Though OUD is a
complex medical illness amenable to treatment, stigma and conflict unfortunately continue to
influence care, frustrate providers,
and marginalize patients.

The Affordable Care Act mandates parity between treatment of
substance-use disorders and that
of other medical illnesses, and the
American Board of Medical Specialties now recognizes addiction
medicine as a medical subspecialty. Since there are not enough
trained addiction medicine physicians to curb the opioid epidemic, we believe education about
evidence-based OUD treatment
should be expanded to all members of the care team and integrated into standard hospital care.
Education coupled with expanded
treatment resources can improve
patients’ experience, increase adherence to treatment recommendations, and improve health outcomes. It is time to put parity
into practice.
Disclosure forms provided by the authors
are available at NEJM.org.
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he United States is facing a
vast epidemic of opioid-related
deaths. More than 2.4 million
Americans have a severe opioiduse disorder (OUD) involving dependence on pain medications,
heroin, or both, and rates of drugoverdose deaths in this country
have outpaced mortality from motor vehicle accidents since 2013.
The rising death toll has been
rivaled in modern history only by
that at the peak of the AIDS epidemic in the early 1990s. Although
these epidemics differ in nature,
the large-scale, highly coordinated
response to AIDS that was eventually mounted may be instructive for combating the opioid epidemic.
In the face of growing alarm
in communities nationwide, the

U.S. Senate recently passed the
Comprehensive Addiction and Recovery Act (CARA), which takes
incremental steps to combat the
epidemic. President Barack Obama
signed it into law in July, despite
the fact that Congress withheld
funding. In his 2017 budget proposal, Obama had incorporated
$1.1 billion for expanding access
to evidence-based care, including medication-assisted treatment
(MAT) using methadone, bupre
norphine, or injectable naltrexone.
Funding would be targeted to
hardest-hit states and those proposing the most promising interventions for getting needed treatment to people with OUD.
Funding is critically important and long overdue — but will
be insufficient without structural
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changes, revised regulations, and
improved services to help connect
marginalized populations with
programs and providers that use
modern, science-based approaches
to treat OUD as a chronic medical condition. Despite the existence of pharmacologic and behavioral treatments based on a
generation of research, most treatment programs do not offer evidence-based care and have minimal physician involvement.1,2 The
substance-abuse treatment system
(programs accredited by the Substance Abuse and Mental Health
Services Administration) has thus
far struggled to implement practices based on science. Too often,
treatment centers operate under
outdated institutional ideologies
favoring abstinence-only approach-
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